Related Experiment Video

Updated: Nov 27, 2025

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory
10:03

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory

Published on: February 28, 2013

26.3K

How Do the Recent Major Randomized Controlled Trials Inform Best Use of the Novel Glucose-Lowering Agents?

Louisa Sukkar1,2, Tamara Young1, Meg J Jardine3,4

  • 1The George Institute for Global Health, UNSW, Newtown, New South Wales, Australia.

Kidney & Blood Pressure Research
|December 3, 2020
PubMed
Abstract

Insights

Newer medications for type 2 diabetes mellitus (T2DM) offer significant cardiac and kidney benefits beyond glucose control. Clinicians can now personalize T2DM treatment to prevent major complications.

Area of Science:

  • Endocrinology
  • Pharmacology
  • Nephrology

Background:

  • Type 2 diabetes mellitus (T2DM) is a major risk factor for cardiovascular disease (CVD) and chronic kidney disease (CKD).
  • Emerging glucose-lowering agents demonstrate significant cardiovascular and renal protective effects.
  • Treatment decisions for T2DM increasingly incorporate benefits beyond glycemic control.

Purpose of the Study:

  • To review the efficacy of three novel medication classes for T2DM.
  • To discuss safety considerations for these new agents.
  • To guide individualized pharmacotherapy selection for T2DM patients.

Main Methods:

  • Review of evidence from high-quality randomized controlled trials.
  • Analysis of efficacy and safety data for new T2DM medication classes.
  • Discussion of clinical decision-making factors.

Main Results:

  • Newer glucose-lowering agents provide benefits for both cardiac and kidney health.
  • Robust clinical trial data support the use of these agents for complication prevention.
  • Individualized treatment selection is crucial.

Conclusions:

  • Novel pharmacotherapies for T2DM present opportunities to mitigate cardiovascular and renal complications.
  • Clinicians must weigh multiple efficacy and safety factors for optimal patient outcomes.
  • Personalized pharmacotherapy selection enhances T2DM management.
Keywords:
Cardiovascular diseaseGlucagon-like peptide-1 receptor agonistsSodium-glucose co-transporter 2 inhibitorsType 2 diabetes

More Related Videos

Author Spotlight: Exploring the Impact of Reduced Resistance Exercise Volume on Metabolic Health06:13

Author Spotlight: Exploring the Impact of Reduced Resistance Exercise Volume on Metabolic Health

Published on: December 1, 2023

1.4K
An In Ovo Model for Testing Insulin-mimetic Compounds06:09

An In Ovo Model for Testing Insulin-mimetic Compounds

Published on: April 23, 2018

10.9K

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
474
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
411
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
438
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
731
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
626
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
386